Osteoclast inhibition for the treatment of bone metastases
Authors:
- O.P. PurohitOPO.P. Purohit
- 1 January 1993
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 19 (1) , 79-103
Abstract
No abstract availableThis publication has 69 references indexed in Scilit:
- The Biochemistry of BoneEndocrinology and Metabolism Clinics of North America, 1989
- Bone Cell PhysiologyEndocrinology and Metabolism Clinics of North America, 1989
- Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD)British Journal of Cancer, 1988
- Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronateBone, 1988
- REDUCED MORBIDITY FROM SKELETAL METASTASES IN BREAST CANCER PATIENTS DURING LONG-TERM BISPHOSPHONATE (APD) TREATMENTThe Lancet, 1987
- Bone metastases: Pathogenesis, treatment, and rationale for use of resorption inhibitorsThe American Journal of Medicine, 1987
- The clinical course of bone metastases from breast cancerBritish Journal of Cancer, 1987
- Etidronate disodium for treating hypercalcaemia of malignancy: a double blind, placebo-controlled studyEuropean Journal of Clinical Investigation, 1986
- Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.Journal of Clinical Oncology, 1986
- Evidence for a high and specific concentration of (Na+,K+)ATPase in the plasma membrane of the osteoclastCell, 1986